Seminar: Targeting Latency-associated Peptide Promotes Antitumor Immunity
June 13, 2017
Time: 4:30PM - 7:00PM
Please join Tilos in welcoming Dr. Galina Gabriely and Dr. Howard Weiner from Brigham & Women’s Hospital for a seminar about the biology that underlies Tilos’s development programs. Drs. Gabriely and Weiner are two of Tilos’s scientific founders, and the seminar will describe LAP, a protein that both defines highly immunosuppressive regulatory T cells and a key control point in the activation of TGFβ. Antibodies specific for LAP are effective in reducing tumor growth in several mouse models and the antibodies have profound effects on the immune response. Tilos believes these antibodies have the potential to play a transformative role in the treatment of cancer. All attendees are invited to stay after the seminar for a reception.